title: Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis.
abstract: Elevated levels of the inducible heat-shock protein 70 (Hsp72) have been implicated in mammary tumorigenesis in histological investigations of human breast cancer. We therefore examined the role of Hsp72 in mice, using animals in which the hsp70 gene was inactivated. We used a spontaneous tumor system with mice expressing the polyomavirus middle T (PyMT) oncogene under control of the mouse mammary tumor virus (MMTV) long-terminal repeat (MMT mice). These mice developed spontaneous, metastatic mammary cancer. We then showed Hsp72 to be upregulated in a fraction of mammary cancer initiating cells (CIC) within the MMT tumor cell population. These cells were characterized by elevated surface levels of stem cell markers CD44 and Sca1 and by rapid metastasis. Inactivation of the hsp70 gene delayed the initiation of mammary tumors. This delay in tumor initiation imposed by loss of hsp70 was correlated with a decreased pool of CIC. Interestingly, hsp70 knockout significantly reduced invasion and metastasis by mammary tumor cells and implicated its product Hsp72 in cell migration and formation of secondary neoplasms. Impaired tumorigenesis and metastasis in hsp70-knockout MMT mice was associated with downregulation of the met gene and reduced activition of the oncogenic c-Met protein. These experiments therefore showed Hsp72 to be involved in the growth and progression of mammary carcinoma and highlighted this protein as a potential target for anticancer drug development.
authors: Department of Medicine, Boston University Medical Center, Boston, MA, USA.
authors: J
authors: J
authors: Gong
authors: Department of Medicine, Boston University Medical Center, Boston, MA, USA.
authors: D
authors: D
authors: Weng
authors: Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors: T
authors: T
authors: Eguchi
authors: Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors: A
authors: A
authors: Murshid
authors: Department of Biochemistry, Boston University Medical Center, Boston, MA, USA.
authors: M Y
authors: MY
authors: Sherman
authors: Department of Medicine, Boston University Medical Center, Boston, MA, USA.
authors: B
authors: B
authors: Song
authors: Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors: S K
authors: SK
authors: Calderwood
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D005260:Female; D050884:HSP72 Heat-Shock Proteins / Q000235:genetics*; D008325:Mammary Neoplasms, Experimental / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000235:genetics*; D009857:Oncogenes / Q000235:genetics; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D050884:HSP72 Heat-Shock Proteins; D019859:Proto-Oncogene Proteins c-met